ライフサイエンスコーパス: aggressiveness

1 aracteristics of the initial cancer type and aggressiveness.

2 t role in sustaining tumor proliferation and aggressiveness.

3 biting and mutual fighting) is influenced by aggressiveness.

4 an observation that correlated with disease aggressiveness.

5 pressed in cancer and correlating with tumor aggressiveness.

6 y was explained by DNA methylation and tumor aggressiveness.

7 strategies and putative biomarkers of tumor aggressiveness.

8 perform two resident-intruder tests to assay aggressiveness.

9 ce and invasiveness, the attributes of tumor aggressiveness.

10 TNBC cells and subsequently attenuates TNBC aggressiveness.

11 ll junctions, and thereby contributes to CRC aggressiveness.

12 ith postprostatectomy GGG and, hence, cancer aggressiveness.

13 >2 cm remained independently associated with aggressiveness.

14 retention as a hallmark of PCa stemness and aggressiveness.

15 activate EMT programs, which increases their aggressiveness.

16 itness of cancer cells and restricting tumor aggressiveness.

17 ellular carcinoma (HCC) recurrence and tumor aggressiveness.

18 arget genes, which may enhance kidney cancer aggressiveness.

19 performed to test alternative definitions of aggressiveness.

20 te cancer cell lines with varying degrees of aggressiveness.

21 -independent role of ABHD5 in modulating PCa aggressiveness.

22 d identification of prognostic indicators of aggressiveness.

23 o amoeboid transition contributing to tumour aggressiveness.

24 ranial and skeletal development, and reduced aggressiveness.

25 cal and pathologic features, including tumor aggressiveness.

26 ameters for evaluating neoplastic growth and aggressiveness.

27 endothelial cells (TECs) regulate tumor cell aggressiveness.

28 tinguish between breast cancers of different aggressiveness.

29 g to increased degree of disorder and cancer aggressiveness.

30 o on quantitative evaluation of autoantibody aggressiveness.

31 astases as well as other indicators of tumor aggressiveness.

32 ease glutamate is a key watershed in disease aggressiveness.

33 ly interfering with pancreatic cancer cells' aggressiveness.

34 rcinomas, in a manner correlating with tumor aggressiveness.

35 sification and provide new insights on tumor aggressiveness.

36 echanism contributing to race-related tumour aggressiveness.

37 ent conditions is well correlated with their aggressiveness.

38 ss to create computed micrographs reflecting aggressiveness.

39 which NF-kappaB pathways promote biological aggressiveness.

40 the levels of which contributes to invasive aggressiveness.

41 linics, to characterize quantitatively tumor aggressiveness.

42 mportant roles in multiple aspects of cancer aggressiveness.

43 llular state associated with increased tumor aggressiveness.

44 erized by subordinate status and the lack of aggressiveness.

45 f therapeutic agents; it also promotes tumor aggressiveness.

46 ables discrimination between prostate cancer aggressiveness.

47 ase-control or case-case analyses of disease aggressiveness.

48 P1 dimer is an important contributor to TNBC aggressiveness.

49 PHG, while high grade alone could not imply aggressiveness.

50 ll marker and seems to correlate with tumour aggressiveness.

51 at itself was associated with prostate tumor aggressiveness.

52 istent T cell exposure to antigen and T cell aggressiveness.

53 degree of inflammation correlates with tumor aggressiveness.

54 expression, high levels of PLD1/2, and high aggressiveness.

55 mics of PCa cells and explain overall tumour aggressiveness.

56 in tumor cell migration, a measure of tumor aggressiveness.

57 ters across multiple days leads to increased aggressiveness.

58 vents associated with tumour progression and aggressiveness.

59 ns-signaling mechanisms, so promoting cancer aggressiveness.

60 fferent aspects of ccRCC biology and disease aggressiveness.

61 (IPA), characteristics associated with tumor aggressiveness.

62 role of genomic instability vis-a-vis tumor aggressiveness.

63 at acts as a robust regulator of cancer cell aggressiveness.

64 ultiple forms of pathology, including cancer aggressiveness.

65 y better knowledge about genes driving tumor aggressiveness.

66 inhibitor 8-azaadenosine reduced cancer cell aggressiveness.

67 l state that prolongs courtship and enhances aggressiveness.

68 eticulum, is an essential regulator of tumor aggressiveness.

69 UHMK1 silencing strongly inhibited GC aggressiveness.

70 effectiveness of cancer treatment and tumor aggressiveness.

71 alters ICMT levels, thereby affecting tumor aggressiveness.

72 s associated with increased ccRCC growth and aggressiveness.

73 s polyamine biosynthesis and prostate cancer aggressiveness.

74 ty and modifying age of diagnosis as well as aggressiveness; 183 reach genome-wide significance.

75 posure induces a persistent increase in male aggressiveness, an effect abrogated by interruption of p

76 umor characteristics, (ii) a marker of tumor aggressiveness and (iii) to look at the impact of adjuva

77 CM), assess their relationship with melanoma aggressiveness and analyze the factors related to TGF-be

78 Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing compar

79 ss may have profound implications for tumour aggressiveness and clinical outcome.

80 ion in early breast cancer can predict tumor aggressiveness and clinical outcomes in large patient po

81 Here we demonstrate that tradeoffs between aggressiveness and defensiveness (i.e., targeting advers

82 cule BUB1B may offer a predictive marker for aggressiveness and effective drug response.

83 d the role of IL4 in promoting breast cancer aggressiveness and how its targeting may improve the eff

84 Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combinat

85 of intra-tumor heterogeneity (ITH) on tumor aggressiveness and immunity independent of tumor mutatio

86 uidity plays an important role for a tumor's aggressiveness and infiltrative potential.

87 pliceosome modulator, E7107, reverses cancer aggressiveness and inhibits castration-resistant PCa (CR

88 so have utility beyond an indicator of tumor aggressiveness and lends itself as a promising therapeut

89 cer (BCa) treatment is based on the presumed aggressiveness and likelihood of cancer recurrence.

90 been regarded as a central factor for tumor aggressiveness and metastasis.

91 tumors, suggesting roles for NCEH1 in tumor aggressiveness and metastasis.

92 rm, LKB1K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination.

93 The acquisition of aggressiveness and metastatic features in breast tumours

94 s a noninvasive tool for evaluation of tumor aggressiveness and monitoring in nonmetastatic PCa.

95 , tumor stiffness) and correlated with tumor aggressiveness and outcome.

96 with glioblastoma development, progression, aggressiveness and patient survival and represents a nov

97 However, it is unclear whether tumor aggressiveness and patient survival are influenced more

98 Osteopontin expression correlates with tumor aggressiveness and poor clinical outcome in patients.

99 vels of miR-194 were associated with disease aggressiveness and poor outcome.

100 rylase (hTP) has been associated with cancer aggressiveness and poor prognosis by triggering proangio

101 therapy and correlates with chemoresistance, aggressiveness and poor prognosis in NSCLC patients.

102 (CDCP1), which has been correlated with the aggressiveness and poor prognosis of multiple carcinomas

103 ved in human tumors and correlate with tumor aggressiveness and poor prognosis.

104 s to identify genetic loci that govern tumor aggressiveness and poor survival.

105 increasingly used clinically to gauge tumor aggressiveness and potentially guide care.

106 vide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR a

107 R1 expression positively correlates with the aggressiveness and progression of prostate tumors.

108 in prostate tumors has been linked to their aggressiveness and progression.

109 plays an important role for prostate cancer aggressiveness and progression.

110 e newly identified Notch3-Pin1 axis in T-ALL aggressiveness and progression.

111 to play a crucial role by increasing cancer aggressiveness and promoting resistance to therapy.

112 ked defects of this pathway to breast cancer aggressiveness and proposed Wnt/PCP signalling as a ther

113 etic age is an important determinant of TNBC aggressiveness and provide rationale for investigating a

114 hough tumor hypoxia is associated with tumor aggressiveness and resistance to cancer treatment, many

115 NANOG, SOX2, and OCT4, associated with tumor aggressiveness and resistance to conventional anticancer

116 c regions within tumors represent sources of aggressiveness and resistance to therapy.

117 tient samples and correlated with markers of aggressiveness and shorter survival.

118 Males differed consistently in activity, aggressiveness and social plasticity.

119 Changes in aggressiveness and specificity of diverse pathogens on c

120 newly established role of SOCS2 in leukemia aggressiveness and stemness raises the possibility that

121 moral inflammatory cells is related to tumor aggressiveness and suggests that the response to treatme

122 g in various organs and with a large span of aggressiveness and survival rates.

123 Individuals vary in aggressiveness and susceptibility to winner-loser effect

124 in a dramatic augmentation in tumor size and aggressiveness and that NAF-1 overexpression enhances th

125 ed by dysregulated SRGs as a hallmark of PCa aggressiveness and the spliceosome as a therapeutic vuln

126 ontributes to key functions related to tumor aggressiveness and the survival of cancer cells.

127 A splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African Ame

128 role for BIRC3 expression as a predictor of aggressiveness and therapeutic resistance to TMZ and RT

129 cular subtypes exhibit differential clinical aggressiveness and therapeutic response, which may have

130 eatment efficacy and potentially with tumour aggressiveness and therefore, accurate noninvasive estim

131 tch1-Zeb1-VEGFA loop decreases breast cancer aggressiveness and thus enhances the efficacy of antiang

132 NF8 is an appealing strategy to tackle tumor aggressiveness and treatment resistance.

133 ment and have been linked to increased tumor aggressiveness and treatment resistance.

134 The interaction between aggressiveness and winner-loser experience did not influ

135 ty traits (exploration behavior, territorial aggressiveness, and aggressiveness during nest defense)

136 abeled 1 to 5 in increasing levels of cancer aggressiveness, and generates a score by summing the lab

137 in the RTK/ERK pathway with prostate cancer aggressiveness, and highlighted the potential importance

138 e mammary epithelial cell tumorigenicity and aggressiveness, and increase breast cancer risk.

139 festations of JMML in terms of age of onset, aggressiveness, and organ infiltration with monocytes/ma

140 ociated with HCC disease progression, cancer aggressiveness, and poorer prognosis of HCC patients.

141 s that mediate therapeutic resistance, tumor aggressiveness, and potential targets for therapy.

142 and is characterized by poor survival, high aggressiveness, and recurrence.

143 ften show varying degrees of heterogenicity, aggressiveness, and response/resistance to therapy.

144 to determine the extent of the disease, its aggressiveness, and the need for any treatment.

145 c Anhydrase 9 (CA9), a known marker of tumor aggressiveness, and the simulations demonstrate that CA9

146 s to stem cell-like dedifferentiation, tumor aggressiveness, and therapy resistance in cancer have su

147 ged as important modulators of breast cancer aggressiveness, and we have investigated the ability of

148 ssociated with higher tumor grade, increased aggressiveness, and worse prognosis.

149 ose expression correlates with breast cancer aggressiveness are divided by micrographs of biomarkers

150 K, and ATF6 are crucial for tumor growth and aggressiveness as well as for microenvironment remodelin

151 mma expression may predict pancreatic cancer aggressiveness, as it positively correlated with advance

152 ringly, both estimates increase with tumor's aggressiveness, as qualified by its stage, grade, and su

153 onspecific, is influenced by an individual's aggressiveness, as well as by experience of winning and

154 ervention is associated with decreased tumor aggressiveness, as well as increased senescence and auto

155 evated levels of genes associated with tumor aggressiveness, as well as with morphogenesis of tissues

156 e risk of prostate cancer, age of onset, and aggressiveness at diagnosis.

157 epoMan and Aurora B is associated with tumor aggressiveness but also exposes a vulnerable target for

158 pes are associated with measures of clinical aggressiveness, but do not perfectly predict patient out

159 : The antiapoptotic protein ARC promotes AML aggressiveness by enabling detrimental cross-talk with b

160 While cancer cells gain aggressiveness by mutations, abundant mutations release

161 e BRCA1-IRIS oncogene promotes breast cancer aggressiveness by recruiting macrophages and promoting t

162 ch as proliferation, angiogenesis and tumour aggressiveness, by downregulating signalling pathways su

163 lycerols (TAG) showed heterogeneity by tumor aggressiveness (case-only heterogeneity P < 0.0001).

164 Furthermore, we develop an aggressiveness classifier consisting of 25 DNA methylati

165 , and identification of molecular markers of aggressiveness could provide valuable biochemical insigh

166 I in the prediction of prostate cancer (PCa) aggressiveness, defined by Gleason Grade Group (GGG).

167 The results suggest that aggressiveness does not compromise learning from recent

168 on behavior, territorial aggressiveness, and aggressiveness during nest defense) in great tits (Parus

169 ar repeatability of exploration behavior and aggressiveness during nest defense, providing strong evi

170 Control variables included sex, age, trait aggressiveness, exposure to violent media, interest in g

171 evolution of tumors with different grade of aggressiveness fostered by a hypoxic niche and provides

172 ntly associated with common markers of tumor aggressiveness (high serum alpha-fetoprotein levels, P =

173 supported by ANXA6+ EVs is predictive of PDA aggressiveness, highlighting a therapeutic target and po

174 High ROCK-myosin II activity correlates with aggressiveness, identifying targeted therapy- and immuno

175 e therapeutic resistance and prostate cancer aggressiveness in AA men.

176 g therapeutic resistance and prostate cancer aggressiveness in AA men.

177 which can address therapeutic resistance and aggressiveness in African-American men with prostate can

178 Ectopic expression of TLK2 leads to enhanced aggressiveness in breast cancer cells, which may involve

179 expression levels are correlated with tumor aggressiveness in carcinoma and aggressive sarcoma; howe

180 GF-beta1 levels are associated with melanoma aggressiveness in CM patients and increased in moderate-

181 ner-loser effects were more influential than aggressiveness in determining initiation of agonistic be

182 correlated with increased proliferation and aggressiveness in ER(+) breast cancer cells.

183 athologic attributes associated with disease aggressiveness in GBM, particularly tumor infiltration (

184 m these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prost

185 ARs) represents an established biomarker for aggressiveness in most common malignant diseases, includ

186 n significantly enhances tumor formation and aggressiveness in mouse models of lung tumor initiation

187 ONEUCT2 drives tumor aggressiveness in NEPC, partially through regulating hyp

188 aggressive (due to DGEs) strongly decreased aggressiveness in opponents (due to IGEs).

189 ata show that S1P signalling promotes tumour aggressiveness in OSCC and identify S1P signalling as a

190 esponse in some malignancies, and with tumor aggressiveness in others.

191 ss or low expression of IGF1R is a marker of aggressiveness in subsets of preinvasive and invasive br

192 ND DATA:: KRAS mutations are related to high aggressiveness in the lung metastasis of CRC.

193 as compared between individuals of different aggressiveness in the RI test and experiences of victory

194 iating role for Pfn1 in promoting tumor cell aggressiveness in the setting of ccRCC.

195 sensitive to modulation of serotonin than is aggressiveness in the shore crab.

196 d androgen concentrations may explain female aggressiveness in this species and give dominant breeder

197 5 gene, is overexpressed and associated with aggressiveness in various endocrine-related tumors, but

198 nosis, and silencing of CD97 reduces disease aggressiveness in vivo.

199 CRPC-like cells increases proliferation and aggressiveness, in vitro and in vivo.

200 ultiple processes associated with metastatic aggressiveness including immune evasion, collective diss

201 n the characteristics associated with tumour aggressiveness, including invasion, migration, and oxyge

202 plicated in processes associated with cancer aggressiveness, including metastasis.

203 hlight a novel mechanism underlying clinical aggressiveness involving a mutated ribosomal protein, po

204 This aggressiveness is in part attributed to the closely inte

205 A key environmental determinant of this aggressiveness is the stromal ecology, which can be eith

206 hybrid E/M phenotype in characterizing tumor aggressiveness is tissue and subtype specific.

207 recent contest experience and that reducing aggressiveness is unlikely to affect how animals experie

208 he link between CINSARC expression and tumor aggressiveness is well established, questions remain abo

209 Lower aggressiveness, lower risks of infanticide from female k

210 Not unlike its reported function as a tumor aggressiveness marker, CD151 in humans thus marks and en

211 purely tumour epithelium-centric metrics of aggressiveness may be incomplete and that incorporating

212 atment determination of renal cell carcinoma aggressiveness may help guide clinical decision-making.

213 diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate compone

214 Cancer aggressiveness may result from the selective pressure of

215 and hypoxia can be a prognostic indicator of aggressiveness, metastasis, and poor response to therapy

216 d the role of spatial heterogeneity in tumor aggressiveness, metastasis, and response to treatment.

217 t temporary behaviors of acute agitation and aggressiveness, named problem behaviors.

218 be one of possible forces to counterbalance aggressiveness of a high mutation rate, resulting in sim

219 eous leukemia stem cell (LSC) pool determine aggressiveness of acute myeloid leukemia (AML).

220 cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells.

221 ural basis of the perceived dangerousness or aggressiveness of animals, which we refer to more genera

222 sults indicate that ASH1L contributes to the aggressiveness of ATC and suggest that ASH1L, along with

223 ve been shown to play a critical role in the aggressiveness of breast cancer.

224 nd TWIST1 are positively correlated with the aggressiveness of breast carcinomas.

225 At least part of the ethnic disparity in the aggressiveness of breast tumors might be transmitted thr

226 anism by which ERalpha signaling reduces the aggressiveness of cancer cells, and demonstrate that C/E

227 our findings offer mechanistic insights for aggressiveness of cancers with MYBL2 amplification, and

228 ergrowth in obesity is linked with increased aggressiveness of certain cancers.

229 both the lymphangiogenesis as the intrinsic aggressiveness of CM tumor cells.

230 epresses TRAILR4 expression and inhibits the aggressiveness of colorectal cancer cells.

231 these signatures may be used to predict the aggressiveness of DCIS, and discuss future perspectives

232 tion to identify a clinical indicator of the aggressiveness of DCIS.

233 senchymal (EMT) transition, correlating with aggressiveness of disease.

234 transfer of specific miRNA that enhance the aggressiveness of glioblastoma.

235 proliferation and reduces tumorigenicity and aggressiveness of HCC cells through ROS overproduction a

236 ion, as a result of increased Oct4, promotes aggressiveness of human SHH tumors.

237 multifocal propensity of PC and categorized aggressiveness of individual PC foci based on DNA methyl

238 cificity, combined with both the general low aggressiveness of invasive P. longicornis towards other

239 transcriptional modulator that increases the aggressiveness of malignant glial neoplasms.

240 ion of patients which can guide the type and aggressiveness of management.

241 models, we demonstrate decreased growth and aggressiveness of miR-200-overexpressing UCS cell lines.

242 in the contribution of EBV infection to the aggressiveness of NPC are discussed in this review.

243 Multiple pathways contribute to the aggressiveness of ovarian cancer, including hypoxic sign

244 did not induce any significant change in the aggressiveness of pancreatic cancer cells.

245 r stem cell (CSC) has been demonstrated with aggressiveness of pancreatic cancer.

246 Increased cancer fitness and aggressiveness of PLC may be achieved by enhancing tumor

247 dentified recurrent mutations that drive the aggressiveness of prostate cancers.

248 tic duet was indicated to be involved in the aggressiveness of PTC, but its prognostic value in PTC-r

249 mice formed papillomas, indicating that the aggressiveness of RDEB-cSCC is mutation-independent.

250 ed risk, differential time to recurrence, or aggressiveness of recurrent HCC in patients with complet

251 al tension and matricellular fibrosis in the aggressiveness of SMAD4 mutant pancreatic tumors and hig

252 Tau seeding activity correlates with the aggressiveness of the clinical disease, and some post-tr

253 pression in NSCLC and the role of OPN in the aggressiveness of the lung cancer cells.

254 oup-specific adjustment of the extent or the aggressiveness of the tumor resection by the neurosurgeo

255 in glioblastoma is associated with increased aggressiveness of the tumor.

256 in expression positively correlates with the aggressiveness of the tumor.

257 rs) recurrence, which reflects the intrinsic aggressiveness of the tumor.

258 may contribute in part to the differences in aggressiveness of the two glioma types.

259 This contributes to the intrinsic aggressiveness of these cells by upregulating Rab27-depe

260 expression of stem cell characteristics and aggressiveness of tumor cells.

261 ne of the most aggressive cancers, where the aggressiveness of tumor has been associated to its high

262 y member 4 depletion diminishes necrosis and aggressiveness of tumors.

263 environment that favours the progression and aggressiveness of tumours.

264 higher TGF-beta1 levels and greater melanoma aggressiveness only in non-obese subjects.

265 ains that are enriched with cancer invasion, aggressiveness or metabolism signaling pathways.

266 n behavior but no differences in territorial aggressiveness or nest defense relative to less exposed

267 t HL and LL females did not differ in either aggressiveness or sociability.

268 vity analyses, however, illustrated that the aggressiveness-outcome association was dependent on the

269 ng of SRSF3, RBM22, PTBP1 and RBM3 decreased aggressiveness parameters in vitro (e.g. proliferation,

270 ay better reflect tumor biologic behavior or aggressiveness rather than tumor burden in metastatic NS

271 ers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect ea

272 oral modifications with ideation slowing and aggressiveness, sometimes contrasting with mild severity

273 re had a strong association with features of aggressiveness such as high grade, hormone receptor nega

274 Pigs (n = 255) were assayed for aggressiveness (tendency to attack in resident-intruder

275 ify a novel pathway sustaining breast cancer aggressiveness that can be therapeutically exploited in

276 lmark of tumor development, progression, and aggressiveness, the pHLIP technology may prove useful in

277 re well-established drivers of breast cancer aggressiveness, therapy resistance, and poor prognosis.

278 hypoxia has been proposed to increase tumor aggressiveness, these data suggest WNT11 as a possible t

279 hypothesized that IH could potentiate cancer aggressiveness through activation of the cyclooxygenase-

280 r discovered mechanisms of SAT1-driven tumor aggressiveness through promotion of expression of both D

281 mechanism by which RCP promotes cancer cell aggressiveness through sequential beta1 integrin stabili

282 whose expression negatively correlates with aggressiveness to create computed micrographs reflecting

283 kinetic parameters that reflect autoantibody aggressiveness to the organism's tissues.

284 Well-differentiated, potentially low-aggressiveness tumors form the heterogeneous molecular c

285 , cognition, treatment intensity, and cancer aggressiveness/type, every 0.1-m/s decrease in gait spee

286 esize that unmeasured heterogeneity in tumor aggressiveness underlies these conflicting results.

287 s display abated in vitro and in vivo tumour aggressiveness, via tumour-macrophage co-culture, migrat

288 Aggressiveness was defined as lymph node (LN) involvemen

289 Increased PDA aggressiveness was dependent on tumor cell-mediated upta

290 identify molecular pathways involved in ARMS aggressiveness, we first characterized the migratory beh

291 ofiles from patient cohorts displaying tumor aggressiveness, we identify and experimentally validate

292 Predictive markers of cancer aggressiveness were identified, including various free f

293 state (e.g. stereotypies, hypervigilance and aggressiveness) were also associated with the gut microb

294 rve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

295 roups, and retaliate by signaling preemptive aggressiveness, which may not be asymmetrically exclusiv

296 s point to CCN3 as a biomarker to predict PC aggressiveness while providing clarity on its role as a

297 thout OSA, and their relationship with tumor aggressiveness, while exploring in vitro effects of solu

298 found to be associated with prostate cancer aggressiveness with the exact or similar pattern in the

299 s molecular-based support for determining PC aggressiveness with the potential to impact clinical dec

300 rols polyamine synthesis and prostate cancer aggressiveness, with potential applications in therapy a